cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.4561701
title: Cav3.2-/- Mouse #337 CA1 EEG recording

description: A Ca<sub>v</sub>3.2-/- mouse (internal #337) was implanted with an intrahippocampal electrode for electrohippocampal CA1 EEG recordings. The differential electrode of the TA10ETA-F20 transmitter (Data Science International, DSI, USA, technical specifications: weight 3.9 g, volume 1.9 cc, input voltage range ± 2.5 mV, channel bandwidth (B) 1–200 Hz, nominal sampling rate (f) 1000 Hz (f = 5 B), temperature operating range 34–41 °C) was positioned at the following stereotaxic coordinates: (+)-lead, caudal − 2 mm, lateral of bregma 1.5 mm (right hemisphere), and dorsoventral (depth) 1.5 mm. The epidural reference electrode was positioned on the surface of the cerebellar cortex at the following stereotaxic coordinates: (−)-lead, bregma − 6 mm and lateral of bregma 1 mm (right<br> hemisphere). The deep tungsten electrodes (FHC, USA) are encapsuled with epoxylite with an<br> impedance of 50–100 kΩ (measured at 1000 Hz) and a shank diameter of 250 μm. For further details on the Ca<sub>v</sub>3.2 mouse model, animal experimentation approval, anaesthesia, transmitter insertion, stereotaxic electrode implantation, postoperative pain management and recovery, please refer to Arshaad MI et al., 2021. EEG data were exported to NeuroScore 3.2.9306-1 (Data Sciences International, DSI, USA). As the NeuroScore file format does not allow free access to the data, we have exported the raw EEG data as asci.-files, so that they can easily be imported in secondary analysis software. Importantly, the exported EEG data represent raw EEG data. No filtering, no artefact detection and/or artefact removal have been carried out. Thus, it is the users responsibility to adequately pretreat the data before further processing and analysis. As described in Arshaad MI et al. (2021), filtering, artefact detection and removal was carried out using NeuroScore before further analysis. The EEG data are presented here as a zip-folder for size reasons. Four EEG recordings are exported: R1 (a first 24h long-term EEG recording 10 days post transmitter implantation), R2 (a second 24h long-term recording 17 days post transmitter implantation), U1 (a 6h EEG recording following the first urethane injection (800 mg/kg i.p.) at day 18 post transmitter implantation), U2 (a 6h EEG recording after a second urethane injection (800 mg/kg i.p.) at day 25 post transmitter implantation). In addition, relative activity values are exported for all four recordings. For details on the recording procedure, please refer to Arshaad MI et al. (2021).
description: {"references": ["Enhanced hippocampal type II theta activity aND altered theta architecture in mice lacking the Cav3.2 T-type voltage-gated calcium channel. Arshaad MI, Siwek ME, Henseler C, Daubner J, Ehninger D, Hescheler J, Sachinidis A, Broich K, Papazoglou A, Weiergr\u00e4ber M. Sci Rep. 2021 Jan 13;11(1):1099. doi: 10.1038/s41598-020-79763-4."]}
DOI: 10.5281/zenodo.4557942
title: Cav3.2+/+ Mouse #146 CA1 EEG recording

description: A Ca<sub>v</sub>3.2<sup>+/+</sup> mouse (internal #146) was implanted with an intrahippocampal electrode for electrohippocampal CA1 EEG recordings. The differential electrode of the TA10ETA-F20 transmitter (Data Science International, DSI, USA, technical specifications: weight 3.9 g, volume 1.9 cc, input voltage range ± 2.5 mV, channel bandwidth (B) 1–200 Hz, nominal sampling rate (f) 1000 Hz (f = 5 B), temperature operating range 34–41 °C) was positioned at the following stereotaxic coordinates: (+)-lead, caudal − 2 mm, lateral of bregma 1.5 mm (right hemisphere), and dorsoventral (depth) 1.5 mm. The epidural reference electrode was positioned on the surface of the cerebellar cortex at the following stereotaxic coordinates: (−)-lead, bregma − 6 mm and lateral of bregma 1 mm (right<br> hemisphere). The deep tungsten electrodes (FHC, USA) are encapsuled with epoxylite with an<br> impedance of 50–100 kΩ (measured at 1000 Hz) and a shank diameter of 250 μm. For further details on the Ca<sub>v</sub>3.2 mouse model, animal experimentation approval, anaesthesia, transmitter insertion, stereotaxic electrode implantation, postoperative pain management and recovery, please refer to Arshaad MI et al., 2021. EEG data were exported to NeuroScore 3.2.9306-1 (Data Sciences International, DSI, USA). As the NeuroScore file format does not allow free access to the data, we have exported the raw EEG data as asci.-files, so that they can easily be imported in secondary analysis software. Importantly, the exported EEG data represent raw EEG data. No filtering, no artefact detection and/or artefact removal have been carried out. Thus, it is the users responsibility to adequately pretreat the data before further processing and analysis. As described in Arshaad MI et al. (2021), filtering, artefact detection and removal was carried out using NeuroScore before further analysis. The EEG data are presented here as a zip-folder for size reasons. Four EEG recordings are exported: R1 (a first 24h long-term EEG recording 10 days post transmitter implantation), R2 (a second 24h long-term recording 17 days post transmitter implantation), U1 (a 6h EEG recording following the first urethane injection (800 mg/kg i.p.) at day 18 post transmitter implantation), U2 (a 6h EEG recording after a second urethane injection (800 mg/kg i.p.) at day 25 post transmitter implantation). In addition, relative activity values are exported for all four recordings. For details on the recording procedure, please refer to Arshaad MI et al. (2021).
description: {"references": ["Enhanced hippocampal type II theta activity aND altered theta architecture in mice lacking the Cav3.2 T-type voltage-gated calcium channel. Arshaad MI, Siwek ME, Henseler C, Daubner J, Ehninger D, Hescheler J, Sachinidis A, Broich K, Papazoglou A, Weiergr\u00e4ber M. Sci Rep. 2021 Jan 13;11(1):1099. doi: 10.1038/s41598-020-79763-4."]}
DOI: 10.5281/zenodo.4557941
title: Cav3.2+/+ Mouse #146 CA1 EEG recording

description: A Ca<sub>v</sub>3.2<sup>+/+</sup> mouse (internal #146) was implanted with an intrahippocampal electrode for electrohippocampal CA1 EEG recordings. The differential electrode of the TA10ETA-F20 transmitter (Data Science International, DSI, USA, technical specifications: weight 3.9 g, volume 1.9 cc, input voltage range ± 2.5 mV, channel bandwidth (B) 1–200 Hz, nominal sampling rate (f) 1000 Hz (f = 5 B), temperature operating range 34–41 °C) was positioned at the following stereotaxic coordinates: (+)-lead, caudal − 2 mm, lateral of bregma 1.5 mm (right hemisphere), and dorsoventral (depth) 1.5 mm. The epidural reference electrode was positioned on the surface of the cerebellar cortex at the following stereotaxic coordinates: (−)-lead, bregma − 6 mm and lateral of bregma 1 mm (right<br> hemisphere). The deep tungsten electrodes (FHC, USA) are encapsuled with epoxylite with an<br> impedance of 50–100 kΩ (measured at 1000 Hz) and a shank diameter of 250 μm. For further details on the Ca<sub>v</sub>3.2 mouse model, animal experimentation approval, anaesthesia, transmitter insertion, stereotaxic electrode implantation, postoperative pain management and recovery, please refer to Arshaad MI et al., 2021. EEG data were exported to NeuroScore 3.2.9306-1 (Data Sciences International, DSI, USA). As the NeuroScore file format does not allow free access to the data, we have exported the raw EEG data as asci.-files, so that they can easily be imported in secondary analysis software. Importantly, the exported EEG data represent raw EEG data. No filtering, no artefact detection and/or artefact removal have been carried out. Thus, it is the users responsibility to adequately pretreat the data before further processing and analysis. As described in Arshaad MI et al. (2021), filtering, artefact detection and removal was carried out using NeuroScore before further analysis. The EEG data are presented here as a zip-folder for size reasons. Four EEG recordings are exported: R1 (a first 24h long-term EEG recording 10 days post transmitter implantation), R2 (a second 24h long-term recording 17 days post transmitter implantation), U1 (a 6h EEG recording following the first urethane injection (800 mg/kg i.p.) at day 18 post transmitter implantation), U2 (a 6h EEG recording after a second urethane injection (800 mg/kg i.p.) at day 25 post transmitter implantation). In addition, relative activity values are exported for all four recordings. For details on the recording procedure, please refer to Arshaad MI et al. (2021).
description: {"references": ["Enhanced hippocampal type II theta activity aND altered theta architecture in mice lacking the Cav3.2 T-type voltage-gated calcium channel. Arshaad MI, Siwek ME, Henseler C, Daubner J, Ehninger D, Hescheler J, Sachinidis A, Broich K, Papazoglou A, Weiergr\u00e4ber M. Sci Rep. 2021 Jan 13;11(1):1099. doi: 10.1038/s41598-020-79763-4."]}
DOI: 10.5281/zenodo.4558201
title: Cav3.2+/+ Mouse #147 CA1 EEG recording

description: A Ca<sub>v</sub>3.2<sup>+/+</sup> mouse (internal #147) was implanted with an intrahippocampal electrode for electrohippocampal CA1 EEG recordings. The differential electrode of the TA10ETA-F20 transmitter (Data Science International, DSI, USA, technical specifications: weight 3.9 g, volume 1.9 cc, input voltage range ± 2.5 mV, channel bandwidth (B) 1–200 Hz, nominal sampling rate (f) 1000 Hz (f = 5 B), temperature operating range 34–41 °C) was positioned at the following stereotaxic coordinates: (+)-lead, caudal − 2 mm, lateral of bregma 1.5 mm (right hemisphere), and dorsoventral (depth) 1.5 mm. The epidural reference electrode was positioned on the surface of the cerebellar cortex at the following stereotaxic coordinates: (−)-lead, bregma − 6 mm and lateral of bregma 1 mm (right<br> hemisphere). The deep tungsten electrodes (FHC, USA) are encapsuled with epoxylite with an<br> impedance of 50–100 kΩ (measured at 1000 Hz) and a shank diameter of 250 μm. For further details on the Ca<sub>v</sub>3.2 mouse model, animal experimentation approval, anaesthesia, transmitter insertion, stereotaxic electrode implantation, postoperative pain management and recovery, please refer to Arshaad MI et al., 2021. EEG data were exported to NeuroScore 3.2.9306-1 (Data Sciences International, DSI, USA). As the NeuroScore file format does not allow free access to the data, we have exported the raw EEG data as asci.-files, so that they can easily be imported in secondary analysis software. Importantly, the exported EEG data represent raw EEG data. No filtering, no artefact detection and/or artefact removal have been carried out. Thus, it is the users responsibility to adequately pretreat the data before further processing and analysis. As described in Arshaad MI et al. (2021), filtering, artefact detection and removal was carried out using NeuroScore before further analysis. The EEG data are presented here as a zip-folder for size reasons. Four EEG recordings are exported: R1 (a first 24h long-term EEG recording 10 days post transmitter implantation), R2 (a second 24h long-term recording 17 days post transmitter implantation), U1 (a 6h EEG recording following the first urethane injection (800 mg/kg i.p.) at day 18 post transmitter implantation), U2 (a 6h EEG recording after a second urethane injection (800 mg/kg i.p.) at day 25 post transmitter implantation). In addition, relative activity values are exported for all four recordings. For details on the recording procedure, please refer to Arshaad MI et al. (2021).
description: {"references": ["Enhanced hippocampal type II theta activity aND altered theta architecture in mice lacking the Cav3.2 T-type voltage-gated calcium channel. Arshaad MI, Siwek ME, Henseler C, Daubner J, Ehninger D, Hescheler J, Sachinidis A, Broich K, Papazoglou A, Weiergr\u00e4ber M. Sci Rep. 2021 Jan 13;11(1):1099. doi: 10.1038/s41598-020-79763-4."]}
DOI: 10.5281/zenodo.4558200
title: Cav3.2+/+ Mouse #147 CA1 EEG recording

description: A Ca<sub>v</sub>3.2<sup>+/+</sup> mouse (internal #147) was implanted with an intrahippocampal electrode for electrohippocampal CA1 EEG recordings. The differential electrode of the TA10ETA-F20 transmitter (Data Science International, DSI, USA, technical specifications: weight 3.9 g, volume 1.9 cc, input voltage range ± 2.5 mV, channel bandwidth (B) 1–200 Hz, nominal sampling rate (f) 1000 Hz (f = 5 B), temperature operating range 34–41 °C) was positioned at the following stereotaxic coordinates: (+)-lead, caudal − 2 mm, lateral of bregma 1.5 mm (right hemisphere), and dorsoventral (depth) 1.5 mm. The epidural reference electrode was positioned on the surface of the cerebellar cortex at the following stereotaxic coordinates: (−)-lead, bregma − 6 mm and lateral of bregma 1 mm (right<br> hemisphere). The deep tungsten electrodes (FHC, USA) are encapsuled with epoxylite with an<br> impedance of 50–100 kΩ (measured at 1000 Hz) and a shank diameter of 250 μm. For further details on the Ca<sub>v</sub>3.2 mouse model, animal experimentation approval, anaesthesia, transmitter insertion, stereotaxic electrode implantation, postoperative pain management and recovery, please refer to Arshaad MI et al., 2021. EEG data were exported to NeuroScore 3.2.9306-1 (Data Sciences International, DSI, USA). As the NeuroScore file format does not allow free access to the data, we have exported the raw EEG data as asci.-files, so that they can easily be imported in secondary analysis software. Importantly, the exported EEG data represent raw EEG data. No filtering, no artefact detection and/or artefact removal have been carried out. Thus, it is the users responsibility to adequately pretreat the data before further processing and analysis. As described in Arshaad MI et al. (2021), filtering, artefact detection and removal was carried out using NeuroScore before further analysis. The EEG data are presented here as a zip-folder for size reasons. Four EEG recordings are exported: R1 (a first 24h long-term EEG recording 10 days post transmitter implantation), R2 (a second 24h long-term recording 17 days post transmitter implantation), U1 (a 6h EEG recording following the first urethane injection (800 mg/kg i.p.) at day 18 post transmitter implantation), U2 (a 6h EEG recording after a second urethane injection (800 mg/kg i.p.) at day 25 post transmitter implantation). In addition, relative activity values are exported for all four recordings. For details on the recording procedure, please refer to Arshaad MI et al. (2021).
description: {"references": ["Enhanced hippocampal type II theta activity aND altered theta architecture in mice lacking the Cav3.2 T-type voltage-gated calcium channel. Arshaad MI, Siwek ME, Henseler C, Daubner J, Ehninger D, Hescheler J, Sachinidis A, Broich K, Papazoglou A, Weiergr\u00e4ber M. Sci Rep. 2021 Jan 13;11(1):1099. doi: 10.1038/s41598-020-79763-4."]}
DOI: 10.5281/zenodo.4557696
title: Bioinformatics Identifies Predictors of Arteriovenous Fistula Maturation

description: Arteriovenous fistulae (AVF) are the preferred access for hemodialysis but still have poor rates of maturation and patency limiting their clinical use. The underlying mechanisms of venous remodeling remain poorly understood, and only limited numbers of unbiased approaches have been reported. Biological Gene Ontology (GO) term enrichment analysis and differentially expressed genes (DEG) analysis were performed for three AVF datasets. A microRNA enrichment analysis and L1000CDS2 query were performed to identify factors predicting AVF patency. The inflammatory and immune responses were activated during both early and late phases of AVF maturation, with upregulation of neutrophil and leukocyte regulation, cytokine production and cytokine-mediated signaling. In men with failed AVF, negative regulation of myeloid-leukocyte differentiation and regulation of macrophage activation were significantly upregulated. Compared to non-diabetic patients, diabetic patients had significantly reduced immune response-related enrichment such as cell activation in immune response, regulation of immune-effector process and positive regulation of defense response; in addition, diabetic patients showed no enrichment of the immune response-regulating signaling pathway. These data show coordinated and differential regulation of genes associated with AVF maturation; different patterns of several pathways are associated with sex differences in AVF failure. Inflammatory and immune responses are activated during AVF maturation and diabetes may impair AVF maturation by altering these responses. These findings suggest several novel molecular targets to improve sex-specific AVF maturation.
DOI: 10.5281/zenodo.4557695
title: Bioinformatics Identifies Predictors of Arteriovenous Fistula Maturation

description: Arteriovenous fistulae (AVF) are the preferred access for hemodialysis but still have poor rates of maturation and patency limiting their clinical use. The underlying mechanisms of venous remodeling remain poorly understood, and only limited numbers of unbiased approaches have been reported. Biological Gene Ontology (GO) term enrichment analysis and differentially expressed genes (DEG) analysis were performed for three AVF datasets. A microRNA enrichment analysis and L1000CDS2 query were performed to identify factors predicting AVF patency. The inflammatory and immune responses were activated during both early and late phases of AVF maturation, with upregulation of neutrophil and leukocyte regulation, cytokine production and cytokine-mediated signaling. In men with failed AVF, negative regulation of myeloid-leukocyte differentiation and regulation of macrophage activation were significantly upregulated. Compared to non-diabetic patients, diabetic patients had significantly reduced immune response-related enrichment such as cell activation in immune response, regulation of immune-effector process and positive regulation of defense response; in addition, diabetic patients showed no enrichment of the immune response-regulating signaling pathway. These data show coordinated and differential regulation of genes associated with AVF maturation; different patterns of several pathways are associated with sex differences in AVF failure. Inflammatory and immune responses are activated during AVF maturation and diabetes may impair AVF maturation by altering these responses. These findings suggest several novel molecular targets to improve sex-specific AVF maturation.
DOI: 10.6084/m9.figshare.14140040
title: Supplementary Material for: Endoscopic Third Ventriculostomy in Infants Less than One Year of Age: A Short Series of 14 Cases

description: <b><i>Background:</i></b> Endoscopic third ventriculostomy (ETV) is currently considered as an alternative to cerebrospinal fluid (CSF) shunt systems in the treatment of obstructive hydrocephalus. This procedure allows the CSF to drain in the basal cisterns and reabsorbed by arachnoid granulations, and avoiding implantation of exogenous material. <b><i>Aims and Objectives:</i></b> The purpose of this study was to assess the success rate of ETV in infants less than 1 year of age with congenital noncommunicating hydrocephalus. <b><i>Material and Methods:</i></b> This study was a 2-year prospective study from August 2017 to July 2019. ETVs were performed in 14 patients younger than 1 year with diagnosis of noncommunicating hydrocephalous. A failure was defined as the need for shunt implantation after ETV. Phase-contrast MRI of the brain was done after 6 months to see patency of ETV fenestration and CSF flow through ventriculostomy. <b><i>Results:</i></b> ETV was tried in 18 patients and successfully performed in 14 patients. Out of the 14 patients, shunt implantation after ETV was performed in 3 patients (failed ETV). In the successful cases, etiology was idiopathic aqueductal stenosis in 8, shunt complications in 2, and 1 case was a follow-up case of occipital encephalocele; the mean age was 7.7 months (range 3–12). In the 3 failed cases, etiology was aqueductal stenosis, mean age was 7.6 months (range 3–11). In all ETVs, failed patients MPVP shunting was done. Follow-up of nonshunted patients was done from 6 to 24 months (mean 15 months). There was no mortality or permanent morbidity noted following ETV. <b><i>Conclusion:</i></b> ETV is a good surgical procedure for less than 1-year-old children.
DOI: 10.6084/m9.figshare.14140040.v1
title: Supplementary Material for: Endoscopic Third Ventriculostomy in Infants Less than One Year of Age: A Short Series of 14 Cases

description: <b><i>Background:</i></b> Endoscopic third ventriculostomy (ETV) is currently considered as an alternative to cerebrospinal fluid (CSF) shunt systems in the treatment of obstructive hydrocephalus. This procedure allows the CSF to drain in the basal cisterns and reabsorbed by arachnoid granulations, and avoiding implantation of exogenous material. <b><i>Aims and Objectives:</i></b> The purpose of this study was to assess the success rate of ETV in infants less than 1 year of age with congenital noncommunicating hydrocephalus. <b><i>Material and Methods:</i></b> This study was a 2-year prospective study from August 2017 to July 2019. ETVs were performed in 14 patients younger than 1 year with diagnosis of noncommunicating hydrocephalous. A failure was defined as the need for shunt implantation after ETV. Phase-contrast MRI of the brain was done after 6 months to see patency of ETV fenestration and CSF flow through ventriculostomy. <b><i>Results:</i></b> ETV was tried in 18 patients and successfully performed in 14 patients. Out of the 14 patients, shunt implantation after ETV was performed in 3 patients (failed ETV). In the successful cases, etiology was idiopathic aqueductal stenosis in 8, shunt complications in 2, and 1 case was a follow-up case of occipital encephalocele; the mean age was 7.7 months (range 3–12). In the 3 failed cases, etiology was aqueductal stenosis, mean age was 7.6 months (range 3–11). In all ETVs, failed patients MPVP shunting was done. Follow-up of nonshunted patients was done from 6 to 24 months (mean 15 months). There was no mortality or permanent morbidity noted following ETV. <b><i>Conclusion:</i></b> ETV is a good surgical procedure for less than 1-year-old children.